abemaciclib + durvalumab + aromatase inhibitor

This is a combination therapy consisting of three agents commonly investigated for the treatment of hormone receptor-positive, HER2-negative breast cancer and potentially other cancers. Abemaciclib is a selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression from G1 to S phase, leading to inhibition of tumor cell proliferation[6][7]. Durvalumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80, thereby enhancing anti-tumor immune responses. Aromatase inhibitors (such as letrozole, anastrozole, or exemestane) are small molecules that inhibit the enzyme aromatase, reducing estrogen production and thus limiting growth stimulation in estrogen receptor-positive tumors[3][4]. This combination aims to target cancer cells through cell cycle arrest, immune checkpoint blockade, and endocrine suppression.

Other names

aromatase inhibitorletrozoleanastrozoleexemestane